EGFR and bone metastasis: Among patients who developed acquired EGFR amplification after first‐generation EGFR‐TKI treatment, 6.8% (4/59) developed liver metastasis, 18.6% (11/59) developed brain metastasis, and 35.6% (21/59) developed bone metastasis.